Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tipifarnib - Kura Oncology

Drug Profile

Tipifarnib - Kura Oncology

Alternative Names: NSC-702818; R-115777; Zarnestra

Latest Information Update: 19 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen L.P.; Janssen-Cilag; Johnson & Johnson
  • Developer Emory University; H. Lee Moffitt Cancer Center and Research Institute; Janssen-Cilag; Johnson & Johnson; Kura Oncology; National Cancer Institute (USA); Samsung Medical Center; Spanish Lung Cancer Group; University of Texas M. D. Anderson Cancer Center
  • Class Amines; Antineoplastics; Cardiovascular therapies; Chlorobenzenes; Imidazoles; Ketones; Quinolines; Small molecules
  • Mechanism of Action Farnesyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; T-cell lymphoma; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Pancreatic cancer
  • Phase II Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Non-small cell lung cancer; Peripheral T-cell lymphoma; Squamous cell cancer; Thyroid cancer; Urogenital cancer
  • Phase I/II Multiple myeloma
  • Phase I Solid tumours
  • Preclinical Hypertrophic cardiomyopathy; Renal cell carcinoma; Rhabdomyosarcoma
  • No development reported Cutaneous T-cell lymphoma
  • Discontinued Breast cancer; Glioblastoma

Most Recent Events

  • 19 Oct 2023 Efficacy and adverse events data from the phase II trial in Squamous cell cancer released by Kura Oncology
  • 17 Oct 2023 Efficacy and adverse events data from a phase II AIM-HN trial in Squamous cell cancer released by Dana Farber Cancer Institute
  • 21 Sep 2023 Kura Oncology terminates a phase I trial in Solid tumours (Late-stage disease) in USA (PO) due to recruitment challenges (NCT04865159)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top